Semaglutide

FDA-approved GLP-1 receptor agonist with the largest clinical evidence base for weight and glycemic outcomes.

Overview

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist originally developed by Novo Nordisk and approved under the brand names Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management). It was the first GLP-1 with clinical trial data showing sustained double-digit percentage body weight reduction, and remains the most clinically studied compound in the class, with the STEP trials showing ~15% average weight loss at 68 weeks at the maintenance dose.

Beyond weight and glycemic effects, semaglutide has shown cardiovascular risk reduction in the SELECT trial, with favorable movement in biomarkers like ApoB, triglycerides, HbA1c, and hs-CRP. These secondary effects are often what matters most for long-term health, and they're the reason serious users track a full metabolic panel rather than just the scale.

The titration schedule is critical - most GLP-1 side effects (nausea, GI intolerance) are concentration- and rate-of-change-dependent. Users who titrate slower than the box recommends almost uniformly report a better experience than those who follow the label exactly. Logging dose, injection date, and side effects alongside biomarkers gives a clear picture of personal response.

Mechanism of Action

Semaglutide mimics endogenous GLP-1, a gut-derived incretin hormone. It acts on pancreatic beta cells (glucose-dependent insulin secretion), alpha cells (glucagon suppression), the hypothalamus (appetite reduction), and the GI tract (delayed gastric emptying). The result is reduced appetite, improved glycemic control, and - over months - sustained weight reduction primarily from fat mass. Cardiovascular benefits appear to be mediated through improved metabolic parameters and direct anti-inflammatory effects on vascular tissue.

Community Usage Patterns

Standard titration per label: 0.25 mg weekly × 4 weeks, 0.5 mg × 4, 1.0 mg × 4, 1.7 mg × 4, then 2.4 mg maintenance. Many users extend each step to 6–8 weeks to minimize GI side effects. Compounded versions from 503A pharmacies are common and typically reconstituted in 2–3 mL of bacteriostatic water. Key tracking: weight weekly, HbA1c and fasting glucose at baseline + 3 months + 6 months, ApoB quarterly.

Education only - not medical advice. Any protocol change should involve your licensed provider.

Deep Dive

The molecular engineering behind a once-weekly dose

Native GLP-1, the gut hormone semaglutide imitates, survives only 1 to 2 minutes in circulation. The enzyme dipeptidyl peptidase-4 (DPP-4) cleaves it almost instantly and the kidneys clear the fragments, which is why the body's own GLP-1 cannot be used as a drug. Semaglutide shares roughly 94 percent of its amino-acid sequence with human GLP-1 but carries deliberate modifications: a substitution at position 8 (2-aminoisobutyric acid replacing alanine) that blocks the DPP-4 cleavage site, a second substitution at position 34, and a C18 fatty-diacid chain attached through a short spacer that lets the molecule bind reversibly to albumin.

Albumin binding keeps semaglutide sequestered in the bloodstream and shielded from renal clearance, stretching the half-life to about 7 days (roughly 165 hours). This one fact explains the weekly schedule, the slow onset, and why steady-state concentrations are not reached until four to five weeks after each dose change. It also explains why side effects track the rate of escalation rather than the absolute dose: plasma levels keep climbing for over a month after every titration step, so a fast escalation stacks a rising concentration on top of an already-adapting gut.

The human evidence base is unusually deep

Most compounds cataloged on this site rest on animal data or small human series. Semaglutide is the opposite, and honesty here means acknowledging how strong the data actually is. The SUSTAIN program (type 2 diabetes) and the STEP program (weight management) together enrolled tens of thousands of participants. SUSTAIN-6 (Marso et al., NEJM 2016, n=3,297) was the cardiovascular-safety trial that first signaled benefit, with a 26 percent lower rate of major adverse cardiovascular events (hazard ratio 0.74). STEP 1 (Wilding et al., NEJM 2021, n=1,961) produced the headline result of roughly 15 percent mean weight reduction at 68 weeks.

Two later trials matter most for the "is this worth it for health, not vanity" question. SELECT (Lincoff et al., NEJM 2023, n=17,604) enrolled people with established cardiovascular disease and overweight or obesity but without diabetes, and reported a 20 percent lower rate of cardiovascular death, heart attack, or stroke. That was the first evidence the class lowers hard cardiovascular outcomes in people without diabetes. FLOW (Perkovic et al., NEJM 2024, n=3,533) reported a 24 percent lower rate of kidney-disease progression in type 2 diabetes with chronic kidney disease (hazard ratio 0.76), and STEP-HFpEF reported symptom improvement in heart failure with preserved ejection fraction. This is a depth of evidence that a research peptide such as BPC-157 or GHK-Cu simply does not have.

One honest caveat sits inside the same dataset. STEP 4 (Rubino et al., JAMA 2021) was a withdrawal trial: participants switched to placebo at week 20 regained roughly two-thirds of the weight they had lost over the following year, while those who continued kept losing. The biology behaves as ongoing management, not a one-time correction.

Biomarkers worth tracking beyond the standard panel

The profile above already lists HbA1c, fasting glucose, ApoB, fasting insulin, LFTs, and weight. A few additions are commonly tracked and round out the picture:

- Body composition, not just scale weight. In the STEP 1 DXA substudy, roughly 40 percent of the weight lost was lean mass and 60 percent was fat mass. Body-composition scanning (DEXA) separates fat loss from muscle loss in a way the scale cannot, which is why body composition rather than scale weight is often the more informative thing to track over time. - Resting heart rate. GLP-1 receptor agonists raise resting heart rate by roughly 2 to 4 bpm on average in trials. A wearable trend line is usually enough to watch it, and a sustained jump is worth raising with a clinician. - hs-CRP. This inflammatory marker fell by roughly 40 to 50 percent across the STEP 1, 2, and 3 trials, and is one of the cleaner signals that the metabolic effect extends past the number on the scale. - Lipase and eGFR. Pancreatitis is uncommon but real, and rapid weight loss can raise gallstone risk. Tracking lipase and kidney function gives early context on the uncommon serious events.

Protocol-design context and the plateau

Weight change on any GLP-1 is not linear. As fat mass falls, resting energy expenditure drops and appetite-regulating signaling partly re-adapts, so most people reach a plateau somewhere between month 6 and month 12. A plateau is expected physiology, not a sign the drug has stopped working. It is also why resistance training and adequate protein intake come up so often in the community: they are the levers most discussed for biasing that 40 percent lean-mass figure downward. All of this is educational context for interpreting your own tracked data. Decisions about dose, duration, and whether the compound is appropriate for you belong with a licensed clinician.

Regulatory status and the 2025 to 2026 compounding wind-down

Semaglutide is FDA-approved as Ozempic (type 2 diabetes, 2017), Rybelsus (oral, 2019), and Wegovy (chronic weight management, 2021). It carries a boxed warning for thyroid C-cell tumors based on rodent studies and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.

The landscape shifted sharply in 2025. During the long-running shortage, 503A and 503B compounding pharmacies were permitted to produce semaglutide. On February 21, 2025 the FDA declared that shortage resolved, which removed the legal basis for that compounding, and the enforcement deadlines that followed (April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities) wound most compounded supply down. Anyone tracking a protocol built around compounded semaglutide should treat sourcing and product identity as an open question and confirm current status with a licensed clinician, because the rules that applied in 2023 and 2024 no longer hold in 2026.

Biomarkers to Track

When running Semaglutide, these are the biomarkers most commonly tracked to assess response and safety:

Blood Work Checklist

Before starting Semaglutide, baseline the right panel. The Peptide Blood Work Checklist covers the full baseline panel, what to add for Semaglutide's class, and when to retest.

Reconstitution Calculator

Free calculator for Semaglutide reconstitution math - vial size, BAC water volume, and exact syringe units.

Side Effects & Monitoring

What Semaglutide side effects are commonly reported, when they appear, the red flags worth a provider call, and the biomarkers that catch issues early.

Results & What to Track

What Semaglutide results actually look like in the data - the markers to measure, when they tend to move, and how to tell a real result from placebo.

Related Reading

• Semaglutide Blood Work Guide →
• Semaglutide Plateau Guide →
• Glp 1 Nausea Guide →
• Glp1 Titration Schedule Guide →

Related Peptides

Semaglutide Head-to-Head Comparisons

Conditions Semaglutide is Commonly Researched For

Frequently Asked Questions

Log doses, upload your lab PDFs, and let StackAI read your panel in context of what you're actually running. Free to start.